Welcome to our dedicated page for Guided Thera SEC filings (Ticker: GTHP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is intended to provide access to U.S. Securities and Exchange Commission (SEC) filings for Guided Therapeutics, Inc. (OTCQB: GTHP), a company in the surgical and medical instrument manufacturing industry that focuses on early disease detection using patented biophotonic technology. While no specific filings are listed in the data provided here, investors typically look to SEC documents to understand a company’s risks, business description and financial condition.
Guided Therapeutics’ business context includes the development and commercialization of the LuViva® Advanced Cervical Scan, a non-invasive device for cervical disease detection at the point of care. In its public communications, the company refers readers to risk factor discussions in its Annual Report on Form 10-K and subsequent filings, where it highlights uncertainties such as the ability to commercialize products or continue as a going concern, the uncertainty of regulatory approval and dependence on licensed intellectual property.
On Stock Titan’s SEC filings page, users can review documents such as annual reports (Form 10-K), quarterly reports (Form 10-Q), current reports (Form 8-K) and registration statements when they are available from EDGAR. These filings often expand on topics mentioned in press releases, including clinical and regulatory developments, commercialization plans for LuViva, and relationships with partners and distributors.
To make these materials easier to work with, this page pairs real-time updates from EDGAR with AI-powered summaries that explain the key points of lengthy filings. Users can quickly see how Guided Therapeutics describes its business, technology, risk factors and financing arrangements without reading every page in detail. When Form 4 insider transaction reports or proxy statements are available, they can also be accessed here, with AI-generated highlights to help interpret executive and director activity in the context of GTHP’s overall disclosure record.
Guided Therapeutics (GTHP) reported Q3 2025 results. Sales of devices and disposables were $60 thousand with gross profit of $35 thousand, while operating expenses reached $520 thousand. The company posted a net loss of $742 thousand for the quarter and $1.978 million for the nine months.
Liquidity remains tight with cash and cash equivalents of $87 thousand and total assets of $903 thousand against total liabilities of $6.549 million. Stockholders’ deficit was $5.646 million. The company disclosed a going concern uncertainty, citing a working capital deficit of about $5.7 million and ongoing operating losses.
To fund operations year-to-date, GTHP raised $260 thousand via private placements and $623 thousand in notes (including related parties), and issued 18.47 million shares from conversions, financing, and interest/dividends paid in stock. Deferred revenue stood at $689 thousand, short-term convertible debt in default was $1.130 million, and 83,599,156 common shares were outstanding as of November 10, 2025.
FAQ
What is the current stock price of Guided Thera (GTHP)?
What is the market cap of Guided Thera (GTHP)?
